Campbell & CO Investment Adviser LLC Takes Position in Repligen Corporation $RGEN

Campbell & CO Investment Adviser LLC bought a new stake in shares of Repligen Corporation (NASDAQ:RGEN) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 6,210 shares of the biotechnology company’s stock, valued at approximately $772,000.

A number of other institutional investors have also recently added to or reduced their stakes in RGEN. Price T Rowe Associates Inc. MD raised its position in Repligen by 6.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 7,566,093 shares of the biotechnology company’s stock valued at $962,711,000 after purchasing an additional 430,039 shares during the period. Alliancebernstein L.P. grew its stake in shares of Repligen by 1.3% in the first quarter. Alliancebernstein L.P. now owns 1,024,180 shares of the biotechnology company’s stock valued at $130,317,000 after buying an additional 13,284 shares in the last quarter. Northern Trust Corp raised its holdings in shares of Repligen by 1.0% during the 1st quarter. Northern Trust Corp now owns 498,447 shares of the biotechnology company’s stock valued at $63,422,000 after buying an additional 4,734 shares during the period. Geneva Capital Management LLC raised its holdings in shares of Repligen by 239.6% during the 2nd quarter. Geneva Capital Management LLC now owns 487,534 shares of the biotechnology company’s stock valued at $60,639,000 after buying an additional 343,991 shares during the period. Finally, Alyeska Investment Group L.P. lifted its position in Repligen by 24.0% during the 1st quarter. Alyeska Investment Group L.P. now owns 460,237 shares of the biotechnology company’s stock worth $58,561,000 after acquiring an additional 89,057 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Stock Performance

RGEN opened at $150.56 on Friday. The stock’s 50 day simple moving average is $140.48 and its 200-day simple moving average is $129.71. The company has a current ratio of 8.59, a quick ratio of 7.32 and a debt-to-equity ratio of 0.26. The stock has a market cap of $8.48 billion, a PE ratio of 7,531.77, a P/E/G ratio of 3.32 and a beta of 1.14. Repligen Corporation has a 1 year low of $102.96 and a 1 year high of $182.52.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share for the quarter, topping analysts’ consensus estimates of $0.42 by $0.04. The firm had revenue of $188.81 million for the quarter, compared to the consensus estimate of $181.23 million. Repligen had a net margin of 0.25% and a return on equity of 4.70%. The business’s revenue was up 21.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.43 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. Sell-side analysts forecast that Repligen Corporation will post 1.72 EPS for the current year.

Wall Street Analysts Forecast Growth

RGEN has been the subject of a number of analyst reports. Evercore ISI upped their price objective on shares of Repligen from $155.00 to $175.00 and gave the company an “outperform” rating in a research report on Tuesday, October 7th. Barclays upped their target price on shares of Repligen from $160.00 to $175.00 and gave the company an “overweight” rating in a research note on Wednesday, October 29th. Jefferies Financial Group set a $160.00 price target on Repligen and gave the stock a “hold” rating in a research note on Tuesday, October 28th. Royal Bank Of Canada restated an “outperform” rating and set a $205.00 price objective on shares of Repligen in a research note on Tuesday, September 2nd. Finally, Stephens raised Repligen to an “overweight” rating and set a $160.00 target price on the stock in a report on Tuesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $173.85.

Insider Buying and Selling at Repligen

In related news, Director Anthony Hunt sold 25,000 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $156.88, for a total value of $3,922,000.00. Following the sale, the director owned 100,743 shares of the company’s stock, valued at $15,804,561.84. The trade was a 19.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 1.20% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.